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RESEARCH ARTICLE
Glycans modify mesenchymal stem cell differentiation to impact
on the function of resulting osteoblasts
Katherine M. Wilson1, Alistair M. Jagger1, Matthew Walker1, Estere Seinkmane1, James M. Fox1,
Roland Kröger2, Paul Genever1 and Daniel Ungar1,*
ABSTRACT
Glycans are inherently heterogeneous, yet glycosylation is essential
in eukaryotes, and glycans show characteristic cell type-dependent
distributions. By using an immortalized human mesenchymal stromal
cell (MSC) line model, we show that bothN- and O-glycan processing
in the Golgi functionally modulates early steps of osteogenic
differentiation. We found that inhibiting O-glycan processing in the
Golgi prior to the start of osteogenesis inhibited the mineralization
capacity of the formed osteoblasts 3weeks later. In contrast, inhibition
ofN-glycan processing in MSCs altered differentiation to enhance the
mineralization capacity of the osteoblasts. The effect of N-glycans on
MSC differentiation was mediated by the phosphoinositide-3-kinase
(PI3K)/Akt pathway owing to reduced Akt phosphorylation.
Interestingly, by inhibiting PI3K during the first 2 days of
osteogenesis, we were able to phenocopy the effect of inhibiting
N-glycan processing. Thus, glycan processing provides another layer
of regulation that can modulate the functional outcome of
differentiation. Glycan processing can thereby offer a novel set of
targets for many therapeutically attractive processes.
KEY WORDS: Glycan processing, Hydroxyapatite, Kifunensine,
Osteogenesis, PI3K signalling
INTRODUCTION
Glycosylation is a ubiquitous post-translational modification of
proteins. Glycans synthetized in the eukaryotic secretory pathway
are credited with several examples of modifying specific protein
functions, such as the folding, stability and targeting of secretory
proteins (Ihrke et al., 2001; Kingsley et al., 1986). Moreover, the
importance of glycanprocessing for thedevelopment of complex life is
well recognized, given many described developmental defects caused
by aberrant glycosylation (Hennet and Cabalzar, 2015). It is also well
documented that protein-linked glycan compositions undergo large
changes during differentiation events in mammals, thereby giving rise
to large cell type-dependent variations in glycan profiles (An et al.,
2012;Hamouda et al., 2013;Hasehira et al., 2012;Wilson et al., 2016).
However, it is largely unknown whether these glycosylation changes
are functionally contributing to the differentiation process itself,
potentially altering the function of the differentiated cells, or are mere
bystanders of cell-specification processes.
Differences in glycosylation are established during glycan
processing, mainly in the Golgi. The inherent heterogeneity of
glycosylation, ensured by the 200-plus enzymes that add or remove
monosaccharides, therebymakes it difficult to assess the contributions
of specific glycans or even glycan types to cellular function. Glycans
can be lipid- or protein-linked, the latter classified as O-linked if the
glycan is attached to Ser/ThrorN-linked forAsn-attached glycans. For
N-glycans, a mannose-rich chain – called an oligomannose glycan – is
established in the endoplasmic reticulum (ER) and trafficked with its
carrier protein to the Golgi. Here, mannoses are trimmed in the cis/
medial-Golgi before addition of N-acetylglucosamine (GlcNAc)
residues in the medial-Golgi. The added GlcNAc residues initiate
branches that form the basis for hybrid and complex N-glycans.
Complex N-glycan chains contain galactose, fucose and lactosamine
modifications, and are commonly terminatedwith sialic acids. If initial
mannose trimming by the enzyme mannosidase I is inhibited, only
oligomannose N-glycans will be present (Elbein et al., 1990). In
contrast, inhibition of the mannosidase II enzyme will favour hybrid
glycan formation (Gross et al., 1983). In mammals, O-glycans are
largely divided into mucin-types and the more specialized
glycosaminoglycans, although other minor types are also present.
Details of mucin type O-glycan processing are less well understood
than those for N-glycans. O-glycan biosynthesis is initiated by an
N-acetylgalactosamine (GalNAc) residue,which, in the case ofmucin-
type O-glycans, is elaborated with galactose and GlcNAc in branched
arrangements to form one of four core structures (Ungar, 2009). These
core structures are further modified by the addition of lactosamine,
sialic acid and fucosemodifications, similar to, but often distinct from,
N-glycans. The processing of mucin type O-glycans can be inhibited
by GalNAc analogues that competitively inhibit the addition of
monosaccharides downstream of the initial GalNAc (Kuan et al.,
1989). Besides the expression and activities of glycan-processing
enzyme subsets, their localization within the Golgi also markedly
influences glycan profiles. Enzyme localization is determined through
vesicular sorting, mediated by the conserved oligomeric Golgi (COG)
tethering complex (Miller and Ungar, 2012). COG mutations have
been shown to result in glycosylation defects in various organisms
(Bailey Blackburn et al., 2016; Belloni et al., 2012; Kingsley et al.,
1986; Struwe andReinhold, 2012;Whyte andMunro, 2001;Wu et al.,
2004) byaffectingmultiple differentglycosylationpathways (Kingsley
et al., 1986; Spessott et al., 2010). This is due to the mis-sorting of
Golgi proteins (Oka et al., 2004), which affects both their final
locations and steady state levels (Fisher and Ungar, 2016).
There is limited evidence for a functional contribution of glycans
to the differentiation process, and this is restricted to terminal glycan
modifications. For example, glycan features such as lactosamine
and fucosylation have been implicated in the self-renewal of stem
cells, and, by implication, in the prevention of differentiationReceived 4 August 2017; Accepted 2 January 2018
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(Hamouda et al., 2013; Kumar et al., 2013; Sasaki et al., 2011).
A particular focus has been on the role of terminal sialic acids.
Sialidase treatment has been shown to reduce osteogenesis (Tateno
et al., 2016) and regulatory T-cell differentiation (Lin et al., 2015).
In contrast, sialylation has been found to inhibit human embryonic
stem cell differentiation (Alisson-Silva et al., 2014). In addition,
immune development also involves sialylation that influences major
histocompatibility complex binding (Moody et al., 2001).
The differentiation of mesenchymal stem cells (MSCs) is a good
model to investigate the contributions of glycans to the
differentiation process. The glycan profiles of these stem cells and
their progeny have been well documented. For example, in MSCs,
∼45% of the N-glycans are oligomannose with 55% complex N-
glycans, this is altered to 30% oligomannose and 70% complex N-
glycans in osteoblasts (Wilson et al., 2016). Osteoblasts differentiate
from MSCs and are responsible for bone generation. MSCs can
receive pro-osteogenic signals, as well as anti-adipogenic and anti-
proliferative cues, to promote differentiation into osteoblast
precursors. Runt-related transcription factor 2 (Runx2) is a key
transcription factor that regulates osteogenesis (Ducy et al., 1997). It
induces the expression of several osteoblast specific genes, for
example, those encoding α1 collagen and bone sialoprotein (BSP;
also known as IBSP). A large body of work has implicated various
signalling pathways in osteogenic differentiation and subsequent
mineralization (Cook and Genever, 2013). In particular, TGF-β
signalling [for example, through bone morphogenetic protein 2
(BMP2), Lee et al., 2000], Wnt signalling (via Wnt3a; Quarto et al.,
2010) and several FGF pathways (Su et al., 2014) all feed into
osteogenesis. The involvement of individual pathways is often
controversial. For example, the phosphoinositide-3-kinase (PI3K)
signalling pathway has been implicated both in promoting
(Hamidouche et al., 2009) and antagonizing (Kratchmarova et al.,
2005) osteogenesis, dependent on the activation state of the pathway
within specific stages of osteogenic differentiation.
Here, we find that alteration of either N- or O-glycan processing
in the Golgi fundamentally influences osteogenic differentiation
of an immortalized human clonal MSC line. While inhibiting
O-glycan processing inhibited functional osteogenic differentiation,
interestingly, the inhibition of an early step in N-glycan processing
altered differentiation to ultimately promote more mineralization in
the formed osteoblasts. This change in differentiation is due to
altered PI3K-mediated signalling in the first days of osteogenic
differentiation, implicating protein-linked glycans in the fine-tuning
of signalling to influence cellular differentiation.
RESULTS
Genetic disruption of the glycosylation synthesis pathway
alters the N- and O-glycan profile of hTERT-MSCs
Altering glycosylation enzyme localization in the Golgi by
interfering with vesicular sorting has the potential to broadly
perturb several different glycan biosynthetic pathways. This can be
used to globally assess the function of glycans in a cell biological
process. Such a perturbation was achieved by knocking down a
subunit of the COG vesicle tethering complex, Cog4, by means of
RNA interference. MSCs exist in a heterogeneous population of
bone marrow stromal cells, including partially differentiated
osteoprogenitors, from which they are hard to distinguish. To help
circumvent any issues associated with MSC heterogeneity, here we
used a highly characterized human clonal MSC line. Y101 cells
were previously immortalized by transduction with human
telomerase reverse transcriptase (hTERT), and represent a
reproducible model of in vitro differentiation (James et al., 2015).
Importantly, glycosylation of the Y101 line is unlikely to be altered
due to immortalization, as comparison of three independent
hTERT-MSC clones with different phenotypes (Y101, Y201,
Y202) has shown no significant differences in their N-glycan
profiles (Wilson et al., 2016). hTERT-MSCY101 clones expressing
one of two different Cog4-specific shRNAs were generated
(Cog4KDshRNA1 and Cog4KDshRNA2). Both Cog4KD MSC
lines have over 60% reduction in Cog4 protein levels compared to
that in wild-type (WT) controls (Fig. 1A). Glycosylation alterations
were first investigated by measuring lectin staining via flow
Fig. 1. Cog4 knockdown in MSCs causes glycosylation
defects. (A) Immunoblot of WT and Cog4KDY101 hTERT-
MSC lysates probed for Cog4. Anti-tubulin was used as a
loading control. (B) WT and Cog4KD Y101 hTERT-MSCs
were stained with 10 µg/ml FITC-tagged VVL or 10 µg/ml
biotin-labelled SNA followed by 5 µg/ml FITC–streptavidin,
and the fluorescence intensity of 105 cells was measured
by FACS. Shown are themedian fluorescence intensities of
the KD cell lines relative to WT. Results are mean±s.e.m.
(n=3). (C) Mass spectrometricN-glycan profiles of FANGS-
released N-glycans from WT (top) and Cog4KD (shRNA1,
middle) Y101 hTERT-MSCs, and osteoblasts derived from
Y101 hTERT-MSCs (bottom). Detailed annotated spectra
of the WT and osteoblast lines have been published in
Wilson et al., 2016, and are reproduced here to serve as a
comparison for the Cog4KD cells. *P<0.05, ***P<0.001.
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cytometry. As expected, both the sialic acid-binding Sambucus
nigra lectin (SNA) and the GalNAc-binding Vicia villosa lectin
(VVL) showed reduced staining in Cog4KD lines (Fig. 1B; Fig. S1).
These indicate changes in mucin type O-glycan and likely also N-
glycan biosynthesis. A recent report with a more detailed
description of the changes in the O-glycan profile of Cog4KD
MSCs confirms these differences, indicating a global alteration of
mucin type protein O-glycosylation (Skeene et al., 2017). To
identify more specific changes in N-glycan processing, Cog4KD
hTERT-MSCs were harvested, and total cellular N-glycans isolated
by filter-aided N-glycan separation (FANGS; Abdul Rahman et al.,
2014). Following permethylation, the glycans were analysed by
matrix-assisted laser desorption ionization–time of flight (MALDI-
TOF) mass spectrometry. The N-glycan profile of Cog4KD cells is
highly similar to that of WT hTERT-MSCs [Fig. 1C, compared here
to the published (Wilson et al., 2016) WT and osteoblast spectra].
No significant differences are seen when individual glycans of
>0.02% abundance are quantified (Table S1), or when the relative
abundance of the different glycan classes is calculated (Fig. S2).
The abundance of higher-mass complex glycans above about
2700 m/z is visibly lower in the Cog4KD spectrum. However, this
difference is not statistically significant when the relative
abundances from multiple repeats are summed up. Interestingly
though, the same class of higher-mass glycan species dominates the
profile of osteoblasts differentiated from the hTERT-MSCs (Wilson
et al., 2016 and Fig. 1C). Given the successful alteration of protein
glycosylation in MSCs, in vitro osteogenesis was used as a model to
assess the impact of glycan biosynthesis modulation on cell
differentiation.
Glycosylation impacts on the mineralization behaviour of
differentiating osteoblasts
As previously reported, Y101 hTERT-MSCs cultured in osteogenic
medium for 3 weeks undergo differentiation into osteoblasts, and
produce hydroxyapatite mineral deposits (James et al., 2015). At the
same time there is a dramatic change in the N-glycan profile of the
cells (Wilson et al., 2016), which could serve as MSC-specific
markers. To assess whether the glycans are also functionally
important during differentiation, the glycosylation defective
Cog4KD Y101 cells were subjected to differentiation conditions.
After culturing in osteogenic medium for 3 weeks, WT cells showed
productive osteogenic differentiation, as visualized by Alizarin Red
staining (Fig. 2A), pink alkaline phosphatase (ALP) staining and
numerous von Kossa-stained brown dots, representing mineralized
calcium phosphate deposits (Fig. 2B). In contrast, the Cog4KD lines
showed minimal Alizarin Red staining and very few von Kossa-
stained deposits, attesting to largely failed mineralization, although
ALP staining was still present (Fig. 2A; Fig. 2B, top right).
Quantification of the eluted Alizarin Red stain confirmed the strong
mineralization defect (Fig. 2A, graph).
Cog4 depletion alters a number of different glycosylation
pathways (Fisher and Ungar, 2016), including N-glycan, O-glycan
(Kingsley et al., 1986) and glycolipid (Spessott et al., 2010)
biosynthesis. We next sought to address which of these specifically
affect differentiation of the Y101 hTERT-MSCs. Cells were
therefore cultured in the presence of various glycan biosynthesis
inhibitors and their differentiation assessed. We have previously
published that inhibiting complex N-glycan biosynthesis by using
swainsonine did not affect mineralization (Wilson et al., 2016).
Inhibiting glycolipid biosynthesis by using N-butyldeoxynojirimycin
(NB-DNJ; Fig. 2B, middle left) had no effect on ALP and von Kossa
staining either. To investigate further the contributions of the N-glycan
processing pathway, the mannosidase I inhibitor kifunensine was used,
which completely inhibits N-glycan processing in the Golgi, but has
no effect on the proliferation rate of cells (Fig. S2A–C,E).
Interestingly, addition of kifunensine during osteogenesis resulted
in visibly more abundant von Kossa staining, indicating increased
mineralization (Fig. 2B, middle right). These observations imply
that complex and hybrid N-glycans and glycolipid glycans are not
responsible for the observed defects in Cog4-depleted cells. In
contrast, inhibiting O-glycan biosynthesis phenocopied the effects
of Cog4 depletion by inhibiting mineralization. Differentiating cells
in the presence of the proteoglycan sulfation inhibitor NaClO3
(Fig. 2B, bottom left) or the mucin type O-glycan synthesis inhibitor
benzyl-O-GalNAc (BG; Fig. 2B, bottom right), led to positive pink
ALP staining, without significant amounts of brown von Kossa
staining. Inhibiting the processing ofmucin type O-glycans again had
no effect on cell proliferation (Fig. S2B,D,E), although the GAG
sulfation inhibitor NaClO3 at the used concentration did slow down
the proliferation of cells upon prolonged incubation (Fig. S2F).
While mineralization is a clear functional consequence of
osteogenic differentiation, its absence does not necessarily mean a
complete ablation of the osteogenic differentiation programme. As
another test, real-time quantitative PCR (qPCR) assays were
performed investigating the expression levels of three mRNAs as
markers of osteogenic differentiation (Kulterer et al., 2007): the
transcription factor Runx2, the growth factor BMP2, and the crystal
nucleator BSP. Despite observing a clear loss of mineralization in
both Cog4KD lines, there was little difference in the expression
patterns of Runx2 between WT and the shRNA1 line. While the
fold-changes for shRNA2 are different, the trends are consistent
with what was seen in both shRNA1 andWT cells (Fig. 2C). Levels
of BMP2 and BSP mRNA did not show sharp changes at 21 days in
shRNA-treated cells as seen inWT, and the effects were opposite for
the two markers (compared to the shRNA, higher in WT for BSP,
lower in WT for BMP2; Fig. 2C, top row). Even less different
compared to controls were BG-treated cells, as no differences in the
levels of the tested markers could be seen (Fig. 2C, middle row). For
the drug treatments, we investigated two further genes, the
transcription factor osterix (also known as SP7) as an additional
early marker, and the crystallization factor osteocalcin as a late
marker (Kulterer et al., 2007). While neither of these showed a
statistically significant difference compared to the untreated controls,
the trend in the osteocalcin gene expression was consistent with the
lack of mineralization (Fig. S3). Indeed, comparing samples on
separate individual days, the decrease in osteocalcin expression on
day 7 and 28 was statistically significant. This change in osteocalcin
expression could be responsible for the reduced mineralization seen
with BG, something future studies could address. Surprisingly,
following kifunensine treatment, which enhanced mineralization
(Fig. 2B), the mRNA levels of Runx2, BSP and osteocalcin were
consistently lower throughout osteogenesis than in control cells.
BMP2 expression did increase in-line with the control after 7 days,
but failed to reach the maximal induction at day 14 (Fig. 2C, bottom
row). Collectively these qPCR-based findings may imply that the
main impacts of Cog4 depletion, as well as kifunensine- and BG-
treatments, are on the process of mineralization rather than
differentiation per se, but they do not rule out a direct involvement
in controlling aspects of cell differentiation.
N- andO-glycosylation directly impact onMSCdifferentiation
The results presented so far implicate bothN-glycan andmucin-type
O-glycan processing in osteoblast functionality, but do not provide
evidence for their involvement in differentiation itself. We noticed
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that most inhibitors had to be added for a period of 48 h prior to
differentiation for effects to be observed, while shorter pre-
treatments had no effect. We reasoned that specific glycan types
could be generated or depleted in this pre-differentiation period,
which could prime the cells for altered differentiation and following
this, osteoblast activity. To test whether specific glycan types are
involved in early differentiation decisions, cells were treated with
glycosylation inhibitors for 48 h prior to addition of osteogenic
medium. Osteogenic differentiation was then continued in the
absence of glycosylation inhibitors for 21 days.
Inhibiting proteoglycan sulfation is known to be important for
osteogenesis (Kumarasuriyar et al., 2009 and Fig. 2B). However,
pre-treatment of Y101 MSCs with the sulfation inhibitor NaClO3
was not sufficient to influence mineralization in the same way as
continuous treatment. Pre-treated cells showed ALP and von Kossa
staining that was indistinguishable from controls (Fig. 3A, second
Fig. 2. Altered glycan processing affects the function of MSC derived osteoblasts. (A) Alizarin Red staining of WT or Cog4KD Y101 hTERT-MSC cells
following a 21 day differentiation experiment in osteogenic medium. Quantification of the eluted Alizarin Red stain is shown in the graph below the image.
Results aremean±s.d. (n=6). (B) ALPand vonKossa staining of Y101 cells or Y101 cells stably expressing aCog4-specific shRNA (shRNA2) following incubation
in osteogenic medium with the indicated inhibitors for 21 days. NB-DNJ, N-butyldeoxynojirimycin; BG, benzyl-O-GalNAc. Scale bar: 100 µm. (C) Real-time
qPCR analysis of mRNA expression levels of indicated genes in the Y101WT or shRNA KD cells. Medium was supplemented with the indicated inhibitors 2 days
prior to the start of and until the end of the differentiation experiments. Averages of triplicate measurements were normalized to the day zero control. Data
represent the mean of the mean of three technical repeats each for two independent biological replicates (each normalized independently to its own control) with
s.e.m. shown. The bar positions marked with ‘X’ are from the 21 day shRNA2 samples that peeled off. All qPCR experiments in Figs 2C and 3B were performed in
parallel, and used the same untreated WT as control. This control is replicated in all three rows of 2C as well as 3B for clarity. *P<0.05, **P<0.01,
***P<0.001 (compared to the control samples are marked with asterisks); all other changes are non-significant.
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row). In contrast, BG and kifunensine pre-treatments (Fig. 3A, third
and fifth rows) had the same effect on decreasing and increasing
mineralization respectively, as continuous treatment with the
inhibitors. Given the markedly reduced expression of osteogenic
marker mRNA levels during continuous kifunensine treatment, we
wondered whether this effect was also recapitulated during the pre-
treatment-only regime. Indeed, the pattern of expression levels of
Runx2, BMP2 and BSP mRNAs were very similar in kifunensine
pre-treated and continuously treated hTERT-MSCs (Fig. 3B), and
similar results were obtained for osteocalcin and osterix as well
(Fig. S3). Together, the mineralization and qPCR data indicate
altered MSC osteogenic differentiation when protein glycosylation
is modified.
To determine the epistatic relationship between the N- and O-
glycan-processing pathways during MSC differentiation, hTERT-
MSCs were co-treated with kifunensine and BG for 48 h in basal
medium, prior to subjecting them to osteogenic medium in the
absence of the glycan-processing drugs for 21 days (Fig. 3A, seventh
row). The lack of positive von Kossa staining at the end of the 21 day
differentiation following dual treatment indicates that O-glycan
processing is dominant over N-glycan processing. Interestingly,
treatment of Cog4KD hTERT-MSCs with kifunensine also did not
rescue the mineralization defect (Fig. 3A, bottom row) suggesting
that disruption of the O-glycan synthesis pathway could likely
contribute to the altered MSC phenotype caused by Cog4
knockdown.
Enhancement of mineralization does not alter the
ultrastructure of the formed mineral
The enhanced mineralization potential of kifunensine-treated MSCs
could be particularly interesting from a therapeutic angle. However,
the reduced levels of established osteogenic markers observed by
qPCR during the same differentiation experiments could indicate a
non-conventional differentiation process, which could potentially
cause abnormal or artefactual mineral formation. ALP is important
for mineralization as it generates the phosphate required for
hydroxyapatite. Histological staining did show ALP to be present
in kifunensine-treated cells (pink staining in ALP- and von Kossa-
stained images in Figs 2B and 3A), and this was confirmed by
western blot analysis (Fig. S4A). On the blot, the level of ALP, as
well as its apparent molecular mass are lower upon continuous
kifunensine treatment, but both of these are reverted to normal in
samples that have only been pre-treated with the drug. Importantly
though, total enzymatic activity is not significantly different in
continuously kifunensine-treated compared to control samples
(Fig. S4B). A possible explanation for this is that altered
glycosylation may impact on ALP enzymatic activity. In
conclusion, it is not simply enhanced phosphate generation that is
responsible for the increased mineralization in kifunensine-treated
cells. Key for the formation of mineral with similar properties to that
naturally formed in bone is the control of hydroxyapatite
organization through collagen fibrils. Importantly, further real-
time qPCR analysis of kifunensine pre-treated and continuously
treated hTERT-MSCs revealed that collagen type I is significantly
upregulated by both treatments (Fig. 4A), suggesting a potential
physiological route for increased mineralization.
Collagen type I is a major constituent of bone, and mutations to
type I collagen are associated with the brittle bone disease
osteogenesis imperfecta (Sykes et al., 1986). Importantly, apatite
nanocrystals nucleate within the collagen gap regions to form an
aligned arrangement parallel to the collagen fibrils (Wang et al.,
2012). This was investigated using bright-field transmission
electron microscopy to characterize the size and shape of the
apatite crystals, and selected area electron diffraction (SAED) to
Fig. 3. N- and O-glycan processing mediate
early steps in differentiation. (A) WT Y101
hTERT-MSCs were pre-treated with the
indicated inhibitors for 48 h before
differentiation was induced in osteogenic
medium in the absence of inhibitors for 21 days
(inhibitors were included for the full 21 days for
comparison where indicated as ‘continuous’).
ALP and von Kossa staining was performed on
the indicated days. The images in the last row
show Cog4KD cells rather than WT. Scale bar:
100 µm (top three rows), 5 mm (bottom five
rows). (B) Real-time qPCR experiments
performed as in Fig. 2C with Y101 cells cultured
in osteogenic medium in the continuous
presence of kifunensine following a 48 h pre-
treatment or pre-treated with kifunensine for
48 h followed by incubation in medium without
kifunensine. The +kif data are repeated from
Fig. 2 for clarity. Data represent averages of
mean±s.e.m. of three technical repeats each for
two independent biological replicates. *P<0.05,
***P<0.001 (compared to the control samples),
all other changes are non-significant.
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unambiguously identify the apatite mineral. High-magnification
transmission electron micrographs of unstained thin sections
following resin-embedding of both kifunensine pre-treated and
control MSCs following threeweeks of osteogenesis were collected.
The appearance of the mineral-covered areas was very similar
between the kifunensine-treated and untreated samples apart from a
generally higher density of the mineral in the drug-treated ones
(Fig. 4B). The form and size of the needle-shaped hydroxyapatite
crystals was measured as 5.40±0.80 nm (mean±s.d.; n=15) for
control and 5.14±1.16 nm (n=17) following kifunensine treatment.
This is in good agreement with the ∼5 nm width reported for
hydroxyapatite crystals in bone specimens (Rubin et al., 2003). To
ascertain that the observed crystals following kifunensine treatment
are bona fide apatite crystals, and have the same crystal form as the
ones found in bone, SAED experiments were carried out. These
showed a strong 002 diffraction ring with a pattern typical of apatite
(Fig. 4C, compare with Chatzipanagis et al., 2016). Discontinuity of
the 002 reflection in the diffraction pattern can determine co-
alignment of the apatite nanocrystals, a feature typically found in
bone (Chatzipanagis et al., 2016; Rubin et al., 2003). This is
generally a difficult experiment in a 2D tissue culture model, as the
amount of deposited mineral is usually not sufficient to observe
directional bias of the crystals. However, the high density of the
mineral deposits generated by kifunensine-treated cells allowed us
to observe an incomplete 002 ring. As expected, this effect is more
clearly visible in the included diffraction pattern of a bone sample
due to the higher amount of ordered mineral in bone compared to the
in vitro cell model (Fig. 4C, compare top and bottom half ). This
indicates that in kifunensine-treated cells crystal orientation starts to
align with that of the collagen fibrils generally regarded as the sites
of nucleation and crystal growth in bone (Weiner and Traub, 1992).
These observations suggest that kifunensine treatment increases
collagen type 1 expression, thereby facilitating the generation of
mineral deposits that possess the correct structure and orientation
bias as required for bone formation.
Identifying the signalling pathway linking N-glycan
processing and osteogenesis
The results so far suggest that kifunensine acts early in the MSC
osteogenic differentiation process. Given that the extracellular
portions of signalling pathways are usually mediated by
glycoproteins, we wondered whether the effects of kifunensine
treatment could be attributed to a particular signalling pathway.
MSC proliferation and osteogenic differentiation have been
associated with several major signalling pathways, including Wnt/
β-catenin, TGF-β–BMP/Smad and tyrosine kinase receptor-
mediated (e.g. FGFR) pathways. We compared the activation
status of these pathways in the first few days of MSC osteogenic
differentiation in the presence of a 48 h pre-treatment with
kifunensine, BG and both inhibitors, or in the absence of a drug
treatment. We reasoned that the pathway responsible for the
mineralization enhancing effects of kifunensine should have an
altered response upon kifunensine pre-treatment, when compared to
untreated or BG pre-treated samples. As expected forWnt signalling
following the induction of osteogenesis, active β-catenin levels did
increase, but there was no marked difference between the various
treatments (Fig. S5A). Similarly, phosphorylation of the MAP
kinases ERK1 and ERK2 (ERK1/2, also known as MAPK3 and
MAPK1, respectively) was not markedly different upon kifunensine
treatment when compared to untreated or BG-treated osteogenic
samples (Fig. S5B). Although treatment with both inhibitors did
lead to reduced ERK1/2 activation after 7 days (Fig. S5B, last lane),
this was not further investigated given the lack of difference between
the other three treatment groups. Moreover, investigating the TGF-β
pathway, we could not detect significant levels of phosphorylated
Smad2 or Smad3 under any of the treatment conditions.
To test for receptor tyrosine kinase signalling, the abundances of
phosphotyrosine (pTyr)-containing proteins were compared
between the treatment groups during the first week of
osteogenesis (Fig. 5A). While there are differences in the overall
intensity of pTyr staining over time, which are independent of the
applied drug treatment, the ratio of the two most intense bands seen
between the 100 and 150 kDa molecular mass markers is
Fig. 4. Mineralization enhancement by kifunensine yields well-structured
mineral deposits. (A) Real-time qPCR analysis of collagen type 1 gene
expression in Y101 cells incubated in osteogenic medium with the indicated
inhibitor treatments. Experiments performed as for Fig. 2C, but for 14 days
only. (B) Transmission electron micrographs of 90 nm thin sections prepared
from Epon Araldite-embedded Y101 cell samples following 21 days of
osteogenic differentiation. Kifunensine treatment was for 48 h prior to start of
differentiation only. (C) Electron diffraction images of a bone sample (bottom
half ) and a sample of the resin-embedded Y101 cells differentiated following
kifunensine pre-treatment (top half ). The positions of three diffraction rings
characteristic for hydroxyapatite are indicated with arrows. The diffraction
image of the cells was taken from the region shown in the right side panel.
**P<0.01, ***P<0.001 (compared to the control samples are marked with
asterisks); all other changes are non-significant.
6
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs209452. doi:10.1242/jcs.209452
Jo
u
rn
a
l
o
f
C
e
ll
S
c
ie
n
c
e
specifically altered. At day two of differentiation in the kifunensine-
treated sample the lower band of the doublet decreases in intensity
relative to the upper band (Fig. 5A,B). Although this changewas not
statistically significant, we decided to follow up on this clear trend.
We speculated that the lower of these two bands could represent the
p110 subunit of PI3K. This speculation is somewhat substantiated
by findings of Kratchmarova and colleagues, based on the
molecular mass and related observations about platelet derived
growth factor (PDGF)-induced tyrosine-phosphorylated proteins in
MSCs (Kratchmarova et al., 2005). Interestingly, that study
implicated the PI3K pathway in the PDGF-dependent inhibition
of osteogenesis (Kratchmarova et al., 2005).
Lowered PI3K phosphorylation would lead to a change in the
levels of phosphorylated Akt family proteins (hereafter Akt), a
downstream effector of PI3K (Franke et al., 1995). Total Akt levels
as well as the phosphorylation state of the two main sites (Thr308
and Ser 473) both change over the course of the first week of
differentiation even in the absence of any other treatments (Fig. 6,
compare with no treatment). However, when the phosphorylation
states were carefully quantified and normalized to both total Akt and
the housekeeping protein tubulin, a change upon kifunensine
treatment did emerge. Both the Thr308 and the Ser473 residues of
Akt had a lower level of phosphorylation 2 days after the start of
differentiation in kifunensine-treated hTERT-MSCs compared to
the untreated and BG-treated cells (Fig. 6). In the case of Akt
Thr308 phosphorylation, this difference even persisted at the 7 day
time point. None of the differences were statistically significant after
only four experimental repeats. Given the stronger effect on pSer473
phosphorylation at 2 days, we increased the sample size for this
phosphorylation site to six, which indeed showed a statistically
significant reduction in phosphorylation after 2 days specifically in
the kifunensine pre-treated sample. This supports the hypothesis
that inhibition of PI3K signalling could be the mechanism by which
Fig. 5. Altered phosphotyrosine signalling early in osteogenesis upon
kifunensine treatment. (A) Y101 cells cultured in osteogenic medium for 0, 2,
7 days were treated with the indicated inhibitors for 48 h prior to the start of
differentiation. Total cell lysates were separated on 10% SDS-PAGE and
immunoblots probed with the phosophotyrosine-specific PY20 antibody. (B)
The intensities of the two major bands between the 100 and 150 kDa
molecular mass markers (marked with arrows, with the apparent molecular
masses indicated) were quantified by using ImageJ, and their ratio charted.
Results are mean±s.e.m. for two independent experiments.
Fig. 6. Altered Akt activation during early osteogenic differentiation
following kifunensine treatment. Cell lysates prepared as in Fig. 5A were
immunoblotted for total Akt as well as for Thr308 and Ser473 phosphorylation
on Akt. Band intensities were quantified by means of ImageJ and averaged
following normalization of the phosphorylation-specific signals to the tubulin
and total Akt signals, followed by normalization to the day zero untreated
sample. Dotted lines indicate where the blot was cut and pasted to move two
lanes from the same blot next to each other. All bands shown in one row are
taken from the same image. Horizontal lines in the bar charts were drawn to
highlight the levels of phospho-Akt in kifunensine pre-treated day 2 samples.
Error bars show s.e.m. for n=4 (all pThr308 samples), n=6 (untreated,
kifunensine and BG treated pSer473 samples), n=3 (double treated pSer473
samples). Asterisk marks the statistically significant (P<0.05) reduction of
pSer473 staining in the kifunensine treated day 2 sample.
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kifunensine treatment alters osteogenesis and enhances consequent
mineralization.
Based on the above observations the PI3K inhibitor wortmannin
was used to attempt to phenocopy the effects of kifunensine. We
first verified that 100 nM wortmannin indeed resulted in a
significant reduction of Akt phosphorylation in the presence of
osteogenic medium (Fig. S6). We then reasoned that the 48 h pre-
treatment with the glycosidase inhibitor would have altered the
glycosylation state of signalling components by the time
differentiation was initiated. This then would have had a
transient effect on the signalling machinery during the first few
days of differentiation. Therefore, wortmannin was applied during
the first 2 days of differentiation onto MSCs that were not treated
with kifunensine, and following 3 weeks of differentiation the
cells were stained with Alizarin Red to allow quantification of the
formed mineral deposits. Treating Y101 cells with 100 nM
wortmannin during the first 2 days of differentiation
significantly increased Alizarin Red staining, and by inference
mineralization (Fig. 7), similar to what was seen with kifunensine
treatment.
DISCUSSION
Our study provides evidence for the functional involvement of
Golgi-based glycan processing in the early steps of cellular
differentiation. Restricting mannosidase I inhibition to the 2 days
prior to the start of differentiation increased mineral formation. It is
evident that the effect of kifunensine pre-treatment is transient, for
example the altered glycosylation of ALP seen upon continuous
treatment disappears when only pre-treatment is applied (Fig. S3A).
These data argue that it is indeed the differentiation programme
itself that glycosylation influenced early on rather than merely
affecting the molecular function of the factors responsible for
mineral formation, which themselves appear later during
differentiation (Cook and Genever, 2013). Given that swainsonine
treatment did not alter the mineralization behaviour of osteoblasts
(Wilson et al., 2016) but kifunensine treatment significantly
increased it, it is not simply the lack of complex glycans driving
the enhancement. Similarly, it is not just the lack of terminal
sialylation, an alteration that has previously been implicated in
differentiation events (Alisson-Silva et al., 2014; Moody et al.,
2001), which drives this differentiation mechanism. Future studies
will have to address exactly which N-glycan species are needed for
enhanced differentiation, although this could well involve a range of
glycans. The N-glycan profiles of three different hTERT-MSC lines
(Y101, Y201 and Y202) are virtually indistinguishable (Wilson
et al., 2016), while their differentiation characteristics are clearly
different (James et al., 2015). Therefore, N-glycans almost certainly
play a modulatory role for differentiation rather than a deterministic
one. Interestingly, a second type of glycan processing, that of mucin
type O-glycans, also modulates differentiation, in this case
inhibiting the generation of functional osteoblasts that are capable
of mineral deposition. This is also due to an early event, as in the
case of mannosidase I inhibition.
Which molecular factors could be responsible for the effects of
altered glycan processing on differentiation of this model cell
system? N-glycan processing has been shown to influence the
signalling behaviour of receptors such as EGFR (Sato et al., 2001)
and cytokine receptors (Partridge et al., 2004). In these cases, the
effect of the glycan is on receptor endocytosis, and mostly depends
on complex N-glycan branching (Lau et al., 2007). This mechanism
by itself is less likely to be relevant given the differences observed
between inhibiting mannosidase I and II, which both eliminate
complex glycan branching. In contrast, ICAM-1-mediated
signalling was significantly altered by limiting its glycans to an
oligomannose form, which directly influenced the interactions with
intracellular partners (Scott et al., 2013). Such a mechanism could
potentially be more relevant in our system. The effects of
glycosylation on receptor/growth factor function are generally
conveyed by lectins that specifically bind to the presented glycans.
Recently the lectin Clec11a (osteolectin) was shown to promote
osteogenesis of MSCs (Yue et al., 2016). The consensus
carbohydrate-binding motif of Clec11a does not conform to either
a galactose specific Gln-Pro-Asp nor a mannose specific Glu-Pro-
Asn sequence (Drickamer, 1992). This makes it difficult to
implicate Clec11a in a mechanism of kifunensine-dependent
increased mineralization before its monosaccharide specificity has
been investigated.
While pinpointing the specific glycoprotein(s) responsible for
mediating the consequences of altered glycan processing is beyond
the scope of this study, it was possible to delineate affected
signalling pathways and their outputs. Using the clonal Y101 MSC
line, rather than a variable mixed MSC population, has the
advantage of well-defined differentiation characteristics (James
et al., 2015) in order to study fundamental cell biological questions.
It is interesting though that most of the tested qPCR markers do not
follow the trend expected from the functional output
of mineralization. For example, O-glycan modulation, which
suppresses mineralization, has no effect on Runx2, BMP2, BSP
and osterix. In contrast, kifunensine in part suppresses the
upregulation of these markers although it promotes increased
mineralization. The late marker osteocalcin could potentially
explain the effects of O-glycan inhibition, as it does show a trend
for lower expression, but it again cannot explain the effects of
kifunensine. The much reduced upregulation of the markers in the
Fig. 7. PI3K inhibition can phenocopy the effect of kifunensine treatment.
Y101 cells were grown in osteogenic medium or control basal medium for
21 days and stained with Alizarin Red. Cells were either untreated, pre-treated
with kifunensine for 48 h, or treated with 100 nM wortmannin for the first
2 days of the differentiation period. Images of representative stained wells
are shown below the quantification of the eluted Alizarin Red. The box
represents the 25–75th percentiles, and the median is indicated by the line.
The mean is indicated by a square. The whiskers show the 5–95th percentiles.
n=8 (n=6 for untreated).
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case of kifunensine could imply a shift of biosynthetic capacity that
would instead, for example, be used to generate collagen, which we
did find to be upregulated. We propose the rather speculative
possibility that in Y101 cells collagen levels are rate-limiting for
mineralization whereas other differentiation induced factors are not.
In line with this reasoning, ALP activity is not limiting here for
increased mineralization. The rebalancing of resources (from
Runx2, BMP2 and BSP towards collagen) through altered glycan
processing could tie in with the established role of the glycan
processing machinery in translating the nutrient state of the cell into
growth cues (Lau et al., 2007).
As Y101 cells are a subclone of MSCs, it is difficult to assess the
overall importance of the uncovered effects on the PI3K pathway for
osteogenesis in a primary MSC mixture. Both pro- and anti-
osteogenic effects of PI3K signalling have previously been reported.
The studies on this have investigated PI3K signalling from different
angles. For example, PI3K was described as an essential pro-
osteogenic signalling component downstream of BMP2 (Ghosh-
Choudhury et al., 2002), Wnt3a (Ling et al., 2010) and integrin
(Hamidouche et al., 2009) signalling. In contrast, PI3K inhibition
was shown to release the inhibition of osteogenesis conveyed by
PDGF activation (Kratchmarova et al., 2005). Thus, the PI3K
pathway could act either positively or negatively on osteogenesis,
dependent on the circumstances. It is also apparent that the MAPK
pathway, which often shares cell surface receptors with the PI3K
pathway can be regulated in opposite ways or even independently of
PI3K (Yokota et al., 2014). What is common in all previous studies
though, is that they investigated PI3K signalling throughout the
studied differentiation program. We can now add a further piece to
this puzzle by showing that a short transient inhibition of PI3K at the
start of osteogenesis can alter differentiation to ultimately enhance
mineralization in the Y101MSC line. Thismodulatory effect of PI3K
signalling is in fact a likely conduit for glycans to influence
differentiation. Thus fine-tuning the balance in signalling pathways is
something that altered glycoforms can potentially accomplish. While
our understanding of these processes is limited at the moment to our
model cell line, representing a subpopulation of MSCs, they could
still be important in the context of varying glycosylation between
individuals, in diseases or ageing. Interestingly, many individuals
suffering rare congenital glycosylation disorders have symptoms
consistent with bone malformations (Coman et al., 2008).
MATERIALS AND METHODS
Chemicals were from Sigma and cell culture reagents from Invitrogen unless
otherwise indicated.
Cell culture, osteogenesis and inhibitor treatments
Y101 hTERT-MSCs (James et al., 2015) were cultured in basal medium
[Dulbecco’s modified Eagle’s medium (DMEM), high glucose, pyruvate,
no glutamine, supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin and 1% Gluta-Max-I]. To induce osteogenic
differentiation basal medium was supplemented with 50 μg/ml ascorbic
acid, 5 mM β-glycerophosphate and 10 nM dexamethasone, and changed
every 3–4 days for the indicated period.
Cog4KD hTERT-MSCs were generated by using MISSION shRNA
lentiviral particles (Sigma, TRCN0000180098 designated shRNA1 and
TRCN0000149947 designated shRNA2) according to the manufacturer’s
instructions. A multiplicity of infection (MOI) of 1 was used for
transduction. Single-cell-derived clones were selected using 2 μg/ml
puromycin. The Cog4 MISSION constructs TRCN0000146949,
TRCN0000423404 and TRCN0000443798 were also used but did not
result in significant Cog4 knockdown.
For treatments with glycosylation inhibitors [kifunensine (Kif, Santa Cruz
Biotechnology, 2 μg/ml), benzyl-2-acetamido-2-deoxy-D-galactose (BG,
2 mM), NaClO3 (25 mM), N-butyldeoxynojirimycin (NB-DNJ, Santa Cruz
Biotechnology, 150 μM)] cells were cultured in basal medium with addition
of the inhibitor for 48 h before the start of differentiation. Following this
treatment the inhibitor was added to osteogenic medium where indicated.
Flow cytometric analysis of lectin binding
All centrifugations were at 450 g for 5 min. Cells were washed twice with
phosphate-buffered saline (PBS), incubated at 37°C for 10 min with washing
buffer [0.2% bovine serum albumin (BSA), 5 mM EDTA in PBS], and
detached cells centrifuged.The cellswere resuspended inPBS, counted and re-
pelleted. All following incubations were at 4°C or on ice. Cells were
resuspended in PBS at 106 cells/ml, 100 μl of the suspensionwas incubated for
15 min before adding 100 μl lectin in washing buffer and incubating in the
dark for 30 min. Following additionof 1 mlwashingbufferand centrifugation,
the pellet was resuspended in 100 μl of washing buffer containing 1 μg/ml
DAPI for FITC-conjugated lectin (Vector Labs) or 5 μg/ml streptavidin-
fluorescein (Vector Labs) for biotinylated lectin and incubated in the dark for
5 min (DAPI, for FITC-lectin) or 30 min (streptavidin–FITC, for biotin-
lectin). Streptavidin–FITC was washed out three times before addition of
DAPI. Following DAPI incubations, 1 ml of washing buffer was added, and
cells were pelleted and resuspended in 400 μl PBS. FACSwas performed on a
CyAn ADP Analyzer (Beckman Coulter) using the 405 and 488 nm lasers.
Cells were gated for forward- and side-scatter to exclude debris and against
405 nm to select live cells. The count versus log 488 nm fluorescence of live
cells was displayed as a histogram and the median fluorescence of this
histogram used in comparisons between samples.
Isolation and analysis of N-glycans by mass spectrometry
N-glycan samples were prepared using FANGS as described previously
(Abdul Rahman et al., 2014). Glycans were then permethylated and
analysed by mass spectrometry as described previously (Wilson et al.,
2016), using an ultraflex III MALDI-TOF mass spectrometer (Bruker).
Spectra were analysed using Flex Analysis 3.3 (Bruker) as described
previously (Wilson et al., 2016). In brief, after assignment of a glycan
structure to the mono-isotopic peak, the intensities of all corresponding
isotopic peaks were summed providing the total peak intensity for a given
glycan. Total peak intensities normalized to the sum of all peak intensities
within a spectrum were averaged between spectra.
Histological staining
All incubations were at room temperature. Stained wells were imaged with a
stereo microscope (Zeiss) or a Leica DMLA upright microscope. Cells for
staining were cultured in 24-well plates.
For alkaline phosphatase (ALP) and von Kossa staining, cells were
washed twice with PBS before a 5 min incubation in ALP stain solution
(0.2 mg/ml naphtol AS-MX in 1% N,N-dimethylformamide, 1 mg/ml Fast
Red TR diluted in 0.1 M Tris-HCl pH 9.2). Following two PBS washes and
fixation (4% paraformaldehyde, 5 min), cells were washed with PBS, then
with water before incubation in 1% silver nitrate on a light box for 30 min.
Following this, cells were washed three times with distilled water, incubated
for 5 min with 2.5% sodium thiosulphate, and following two distilled water
washes, stored in PBS with 20% glycerol.
For Alizarin Red staining, following two PBSwashes and 15 min fixation
in 4% paraformaldehyde, cells were washed three times with PBS before a
20 min incubation in 40 mM Alizarin Red S (pH 4.2, reagent filtered and
pH adjusted every week). Cells were washed at least five times in tap water
until excess stain was removed, then air dried. Stain was eluted following
imaging by a 2 h incubation in 10% cetylpyridinium chloride and quantified
by measuring absorbance at 570 nm. If the absorbance was too high, all
samples were equally diluted in water and re-measured.
MTT assay
For each cell line tested, 1200 cells were seeded per well, into six wells of a
96-well culture plate. After the indicated number of days, culture medium
was replaced with 100 μl fresh medium and 25 μl 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/ml in PBS).
Plates were then incubated for 3 h at 37°C in 5% CO2. MTT solution and
medium was removed from wells, and 100 μl of 0.04 M HCl in isopropanol
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was added to each well. Plates were left to shake at room temperature for
10 min to allow for complete solubilization. Absorbance was then read at
570 nm, and average absorbance (with standard deviation) was used in
comparisons.
Analysis of gene expression by real-time qPCR
RNAwas extracted from cells cultured in a well of a six-well plate by using
TRIzol (Invitrogen), and suspended in 12 μl nuclease-free water (Hypure,
ThermoScientific). RNA was treated with RQ1 RNase-free DNase I
(Promega) before using 1 μg for SuperScript II (Invitrogen) catalysed cDNA
synthesis. Real-time qPCR was performed with Fast SYBR Green (Applied
Biosciences) on a StepOnePlus system (Applied Biosciences) and analysed
using StepOne v2.3 software. Gene expression levels were quantified by
using the comparative CT (ΔΔCt) method, by normalizing both to the
housekeeping gene RPS27a andWT (or untreated) day 0 levels. Primer pairs
(given 5′–3′) were: Runx2, AGTGATTTAGGGCGCATTCCT and
GGAGGGCCGTGGGTTCT; BMP2, ACTCGAAATTCCCCGTGACC
and CCACTTCCACCACGAATCCA; BSP, GAGGAGGAAGAGGAA-
GGAAATG and TGGTACTGGTGCCGTTTATG; osterix, GCCAGAA-
GCTGTGAAACCTC and GCTGCAAGCTCTCCATAACC; osteocalcin,
AGGGCAGCGAGGTAGTGAAG and AGGGGCAAGGGGAAGA-
GGAAAG; collagen 1A1, CAAGAACCCCAAGGACAAGAG and
CTTGCAGTGGTAGGTGATGGTC; RPS27a, TGGATGAGAATGGCA-
AAATTAGTC and CACCCCAGCACCACATTCA.
Analysis of protein expression by western blotting
Sample buffer (150 µl; 5% glycerol, 50 mM Tris-HCl pH 6.8, 50 mMDTT,
1% SDS, 0.7 mMBromophenol Blue) was used to lyse cells from awell of a
24-well plate. Proteins were separated on 10% gels prior to semi-dry transfer
onto polyvinylidene fluoride (PVDF)membrane (ThermoFisher) for 60 min
at 20 V using 48 mM Tris-HCl, 39 mM glycine, 20% methanol and
0.0375% SDS as the transfer buffer. Membranes were blocked using PBS
with 0.05% Tween-20 and 5% milk (PBSTM) for 1 h (3% BSA was used
instead of milk for blots with the anti-pTyr PY20 antibody), then incubated
with primary antibody: affinity purified anti-Cog4 (1:500, Miller et al.,
2013), anti-tubulin (1:2000, gift from M. Gerard Waters, Princeton
University, Princeton, NJ), anti-ALP (1:6000, Santa Cruz Biotechnology
sc-137213), anti-active β-catenin (1:2000, Millipore 050665), anti-
phosphotyrosine (1:1000, with 3% BSA instead of milk, BD Bioscience
clone PY20), anti-Akt (1:1000, Santa Cruz Biotechnology sc-1618), anti
Akt-pThr308 (1:1000, Cell Signaling 13038), anti-Akt-pSer473 (1:1000,
New England Biolabs 4060P) anti-pSmad2/3 (1:500, Santa Cruz
Biotechnology sc-11769), anti-pERK (1:4000, R&D Systems AF1018) in
PBSTM overnight at 4°C. Following six 10 min washes with PBSTM,
appropriate HRP-linked secondary antibody (1:3000, Bio-Rad) in PBSTM
was added for 1 h, then the blot was washed, and imaged on a GeneGenius
Chemi-imager (Syngene) after application of Immobilon HRP substrate
(Millipore). Quantification was carried out using ImageJ software.
Electron microscopy
Following 3 weeks of osteogenesis, cells were embedded in Epon Araldite
(EMS), and 90 nm thick sections were placed onto 200 mesh carbon-coated
copper grids. Grids were imaged on a JEOL 2010 TEM operated at 200 kV
with a LaB6 crystal as electron source and an UHR lens for an ultimate
spatial resolution of 1.9 Å. Selected area electron diffraction patterns to
identify the mineral phase were recorded at a camera length of 0.25 m.
Crystal width was quantified by using ImageJ. The distance between points
of half-maximum intensity on lines plotted perpendicular to the long axis of
the crystals was determined, averaged and then multiplied by two to give
crystal width.
Statistical analysis
Data were analysed using SigmaPlot 12.3 software. First, a normality test
(Shapiro–Wilk) and a test of equal variance was performed. For comparison
of two groups, a Student’s t-test was used; for more groups, a one-way
ANOVA test was performed, followed by Holm–Sidak post-hoc tests if
required. If the data failed the normality or variance tests, a Mann–Whitney
test was carried out when two groups were compared, and a Kruskal–Wallis
one-way analysis of variance on ranks, followed by Dunn’s post-hoc test
was carried out if more than one group was being compared. *P<0.05,
**P<0.01 and ***P<0.001, ns, non significant.
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Supplementary Figure 1. Glycan analysis of Cog4KD cells using fluorescent lectins. 
WT (black), Cog4KDshRNA1 (pink) and Cog4KDshRNA2 (brown) Y101 hTERT-MSCs were 
probed with SNA (top) and VVL (bottom) lectins. Histograms show cell counts versus log FITC 
fluorescence. 
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Supplementary Figure 2. Effects of glycan processing 
inhibitors on glycans and cell proliferation in Y101 
hTERT MSCs. 
(A) Quantification of glycan classes in the N-glycan 
profiles of WT, Cog4KD and osteogenically differentiated 
Y101 hTERT-MSCs as well as WT cells treated with 
kifunensine. Error bars are SEM for n=5 (hTERT-MSC) 
or n=3 (all others). The WT and osteoblast N-glycan 
quantifications have been published in (Wilson et al., 
2016), and are reproduced here for comparison. (B-D) 
Bright-field images of cells stained with crystal violet 
following continuous treatment with the indicated 
inhibitor. (E-F) Results of MTT assays comparing 
untreated and continuously inhibitor treated cells. 
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Supplementary Figure 3. Analysis of early and late differentiation markers in drug 
treated cells during osteogenic differentiation. 
Quantitative real-time PCR analysis of mRNA expression levels of the early marker 
osterix and the late marker osteocalcin in Y101 hTERT-MSCs. Medium was 
supplemented with the indicated inhibitors two days prior to the start of differentiation, 
and where indicated continuously kept in the medium until the end of the differentiation 
experiments. Averages of triplicate measurements were normalized to the day zero 
control. The error bars are the SEM for three independent measurements, each 
normalized independently to its own control. None of the differences are statistically 
significant when the whole datasets are analysed. When samples are compared within a 
day the untreated samples are statistically significantly different from the drug treated 
ones on days 7 and 28 for osteocalcin. 
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Supplementary Figure 4. Effect of kifunensine treatment on ALP activity and protein levels. 
(A) Western blots of cells cultured in osteogenic medium for the indicated time and probed with anti-ALP antibody. 
Kifunensine treatment was continuous (top) or for 48 h pre-treatment only (bottom).  Beta-tubulin was used as a 
loading control, L = protein molecular weight marker. (B) ALP activity inY101 cells cultured in osteogenic medium 
±kifunensine for the indicated time was measured using pNP assay and normalized to DNA content determined using 
a pico-green assay. One way ANOVA, n=6, ns= non-significant, error bars show standard deviation. 
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Supplementary Figure 5. Wnt/Ȼ-catenin and MAPK signalling are unperturbed by 
the tested glycosylation inhibitions during early osteogenesis. 
Cells were grown and blotted as in Fig 5, Ȼ-tubulin was used as a loading control. Blots 
were probed for (A) active Ȼ-catenin (n=2) and (B) phosphorylated ERK (n=1). 
 
 
Supplementary Figure 6. Wortmannin inhibition of PI3K during early osteogenesis. 
Y101 hTERT-MSCs were cultured for 6 h in osteogenic medium in the presence or 
absence of 100 nM wortmannin and the phosphorylation state of Akt assessed (top). pAkt 
signals were quantified relative to the 0 h time-point run on the same gel following 
normalization to Ȼ-tubulin and total Akt levels. Error bars represent SEM for n=3 (S473) 
and n=6 (T308). 
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